Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGolimumab (Simponi): Anti-TNF-alpha mAb approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Formulary , 06/09/09
Tumor necrosis factor (TNF)-alpha is a mediator of articular inflammation in chronic inflammatory diseases. Golimumab is a human monoclonal antibody that binds to human TNF-alpha, thus inhibiting its activity. Golimumab was approved on April 2009, for use alone or in combination with methotrexate for the treatment of adult patients with active psoriatic arthritis, for use in combination with methotrexate for the treatment of adult patients with moderately to severely active rheumatoid arthritis, and for the treatment of adult patients with active ankylosing spondylitis.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Sponsor
Article Search
Sponsor